Our finding that Pim inhibition abrogates induction of C-NHEJ activity by topoisomerase 2 inhibitor treatment in cells with FLT3-WT is consistent with this finding in prostate cancer and peripheral T-cell lymphoma cells. Here, FLT3 is linked to prostate cancer.